News Desk
The Dose is the daily news publication of GLP1 Clinics, delivering timely coverage of the GLP-1 medication landscape. From FDA approvals and clinical trial results to insurance policy changes and drug pricing updates, The Dose keeps patients and providers informed about developments that affect access to weight loss treatment.
Eli Lilly's oral GLP-1 pill Foundayo outperformed Novo Nordisk's oral semaglutide in head-to-head diabetes trials, setting up a second FDA submission by month's end.
CMS shelves the Medicare Part D portion of the BALANCE model after major insurers decline, extending the temporary Bridge program through 2027 at $50/month copays.
FDA grants Apotex first tentative approval for generic semaglutide injection, potentially cutting Ozempic costs by 40-60% once patent barriers clear.
